VEGFA and breast carcinoma: As stated above, perhaps the reason for bevacizumab’s inefficacy at treating breast cancer is the VEGF paradox; the paradox states that anti-VEGF drugs commonly target the classical pathway while simultaneously upregulating the VEGF-NRP pathway, which supports CSC maintenance.